Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivipansel PK in Renal Impairment
NCT02813798Phase 1Completed
- Sponsor
- GlycoMimetics
- Start
- Jun 2016
- Primary completion
- Feb 2018
- Modality
- Bivalent/Multivalent Binders, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivipansel in sickle cell disease (SCD) (4 arms), sponsored by GlycoMimetics. Primary endpoints: Area under the concentration-time curve, Clearance (CL) and 2 more. Started Jun 2016; status: completed.
02
Drugs
rivipansel
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02813798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02813798.